Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RECENTLY DISCLOSED LONGER-TERM REVEAL PART A DATA DEMONSTRATED BROAD, MULTI-DOMAIN FUNCTIONAL IMPACT THAT DEEPENED OVER TIME THROUGH 12 MONTHS POST-TSHA-102 REGARDLESS OF AGE OR DISEASE SEVERITY

TAYSHA GENE THERAPIES ANNOUNCES MULTIPLE PRESENTATIONS HIGHLIGHTING ITS TSHA-102 CLINICAL PROGRAM AT THE 2026 IRSF RETT SYNDROME SCIENTIFIC MEETING

DALLAS, JUNE 24, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 32,500,001 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $6.00 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE 833,333 SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $5.999 PER PRE-FUNDED WARRANT, IN EACH CASE BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES ARE BEING OFFERED BY TAYSHA. IN ADDITION, TAYSHA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 5,000,000 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERING TO TAYSHA ARE EXPECTED TO BE APPROXIMATELY $200.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 26, 2026, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

TAYSHA GENE THERAPIES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

DALLAS, JUNE 24, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200.0 MILLION SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SECURITIES WILL BE OFFERED BY TAYSHA. TAYSHA ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING UNDER THE SAME TERMS AND CONDITIONS (INCLUDING SHARES UNDERLYING THE PRE-FUNDED WARRANTS). THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING.

TAYSHA GENE THERAPIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

DALLAS, JUNE 22, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THE COMPLETION OF DOSING IN THE REVEAL PIVOTAL TRIAL AND REPORTED POSITIVE LONGER-TERM CLINICAL DATA FROM PART A OF THE REVEAL PHASE 1/2 TRIALS EVALUATING TSHA-102 FOR THE TREATMENT OF RETT SYNDROME.

TAYSHA GENE THERAPIES ANNOUNCES COMPLETION OF DOSING IN REVEAL PIVOTAL TRIAL AND REPORTS LONGER-TERM CLINICAL DATA FROM PART A OF REVEAL PHASE 1/2 TRIALS EVALUATING TSHA-102 FOR RETT SYNDROME

DALLAS, JUNE 05, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED FOUR NEW EMPLOYEES, IN THE AGGREGATE, RESTRICTED STOCK UNITS (RSUS) REPRESENTING 714,700 SHARES OF THE COMPANY'S COMMON STOCK AND AN OPTION TO PURCHASE 468,600 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE RSUS AND STOCK OPTION WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

DALLAS, MAY 06, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE.

TAYSHA GENE THERAPIES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, MAY 01, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON MAY 1, 2026, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED FIVE NEW EMPLOYEES, IN THE AGGREGATE, RESTRICTED STOCK UNITS (RSUS) REPRESENTING 188,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE RSUS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

DALLAS, APRIL 29, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON WEDNESDAY, MAY 6, 2026, AT 8:30 AM EASTERN TIME.

TAYSHA GENE THERAPIES TO RELEASE FIRST QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON MAY 6

IN VITRO DATA DEMONSTRATED SELF-COMPLEMENTARY AAV9 (SCAAV9) ENABLED ~30-FOLD HIGHER MECP2 PROTEIN EXPRESSION COMPARED TO SINGLE-STRANDED AAV9 (SSAAV9), SUPPORTING THE ABILITY TO EFFECTIVELY DELIVER TSHA-102 TO THE CNS BY LUMBAR IT ADMINISTRATION

TAYSHA GENE THERAPIES TO PRESENT NEW PRECLINICAL DATA SUPPORTING CONSTRUCT DESIGN OF TSHA-102 FOR RETT SYNDROME AT THE ASGCT 2026 ANNUAL MEETING

DALLAS, APRIL 03, 2026 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON APRIL 1, 2026, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED FOUR NEW EMPLOYEES, IN THE AGGREGATE, RESTRICTED STOCK UNITS (RSUS) REPRESENTING 300,000 SHARES OF THE COMPANY'S COMMON STOCK AND AN OPTION TO PURCHASE 92,400 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE RSUS AND STOCK OPTION WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Taysha Gene Therapies, Inc.

TSHA

Price

Financial Reports

No items found.

Press Releases

Taysha Gene Therapies, Inc.

TSHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TSHA